Bharat Biotech, an Indian pharmaceutical company, is seeking international manufacturing allies. This is because India, with proper support, can scale up the production of Covaxin to a billion doses per year. Covaxin is the first indigenous vaccine, created by the company in conjunction with ICMR.
Covaxin has won the approval of being used as an emergency vaccine. Notwithstanding this, Bharat Biotech has wrestled to amp up its production.
“We want to ensure that Bharat Biotech can ably meet the demand for Covaxin such that individuals across the country, and the globe, have access to the vaccine,” said Bharat Biotech’s managing director Krishna Ella.
In a heavily populated country like India, swift production of vaccine batches is the need of the hour.
India has jabbed over 63 crore Covid-19 vaccine citizens , declared Union ministry of Health. International manufacturing giants are thus being welcomed to facilitate the fulfillment of this aim.
(Image credits: Wikipedia)
